Loading company details...
Latest Form 4 (Oct 22, 2026): Douglas Kerr (Head of R&D and CMO): Grant/Award of 8,000 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 22, 2026 | Douglas Kerr, Head of R&D and CMO | Grant/Award | 8,000 | n/a |
| Oct 6, 2026 | Brian S. Posner | Purchase | 2,500 | $40.0K |
| Sep 8, 2026 | Johanna Friedl-Naderer, Chief Commercial Officer | Sale | 900 | $21.9K |
| Sep 8, 2026 | Douglas Kerr, Chief Medical Officer | Sale | 3,745 | $91.2K |
| Sep 8, 2026 | John Cox, CEO & President | Sale | 5,658 | $106.8K |
| Aug 17, 2026 | Jason P. Rhodes | Sale | 268,354 | $7.03M |
| Aug 17, 2026 | Johanna Friedl-Naderer, Chief Commercial Officer | Sale | 226 | $5.9K |
| Aug 17, 2026 | Douglas Kerr, Chief Medical Officer | Sale | 1,556 | $40.9K |
| Aug 17, 2026 | John Cox, CEO & President | Sale | 4,986 | $131.0K |
| Aug 17, 2026 | Erick Lucera, Chief Financial Officer | Sale | 1,797 | $47.2K |